The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 August 2025, approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) by an average of three years in adults and children aged 8 years and older with Stage 2 T1D. Teplizumab is the UK’s first-ever approved immunotherapy for type 1 diabetes.

Stage 3 T1D is when people usually begin to experience blood sugar problems and are diagnosed with the condition, which often requires lifelong insulin treatment.

Teplizumab is used in people with Stage 2 T1D, which is an earlier stage of the disease where individuals are at high risk of progressing to Stage 3.

This medicine has been approved through the International Recognition Procedure (IRP). The IRP allows the MHRA to take into account the exper

See Full Page